SavedAdd your journal

Journals / İnfeksiyon Dergisi / 2006 / Cilt: 20 - Sayı: 3

Adverse effects of antiretroviral drugs

Antiretroviral ilaçların yan etkileri

Nesrin TÜRKER
Bahar ÖRMEN
Pages
219–226
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, the most common adverse effects of antiretroviral thearpy and their managemet are summarized.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The most common problem in the treatment of Human Immunodeficiency Virus (HIV) infection is drug adverse effects.
📊
Key Findings & Data:The most common problem in the treatment of Human Immunodeficiency Virus (HIV) infection is drug adverse effects.
💡
Conclusion & Impact:In this article, the most common adverse effects of antiretroviral thearpy and their managemet are summarized.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The most common problem in the treatment of Human Immunodeficiency Virus (HIV) infection is drug adverse effects. In this article, the most common adverse effects of antiretroviral thearpy and their managemet are summarized.

Özet

mmun Yetmezlik Virüsü (HIV) İnfeksiyonunun tedavisi sırasında en sık karşılaşılan problem ilaç yan etkileridir. Bu makalede, en sık gözlenen antiretroviral ilaç yan etkileri ve bunların yönetimi özetlenmiştir.

🔖

Cite This Article

TÜRKER, N., ÖRMEN, B. (2022). Adverse effects of antiretroviral drugs. İnfeksiyon Dergisi, Cilt: 20 - Sayı: 3, 219–226. https://ajindex.com/articles/546430

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Schieferstein C. Management of side effects. In: Hoffmann C, Kamps BS, eds. HIV Medicine 2003. Paris: Flying Publisher, 2003: 247-80
  2. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 -infected patients. AIDS 2001; 15: 71 -5
  3. Boubaker K, Sudre P, Bally F, et al. Changes in renal function associated with indinavir. AIDS 1998; 12: 249-54
  4. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35: 269-73
  5. Sartori WIT, Mares M, Zerbinati P. Report on a 3-year follow-up zidoyudine (AZT) treatment in a group of HIV-positive patients with congenital clotting disorders. Haematologia (Budap) 1994; 26: 17-27
  6. Najean Y, Rain JD. The mechanism of thrombocytopenia in patients with HIV infection. J Lab Clin A//ecM994; 123: 415-20
  7. Anonymous. Adverse drug effects. In: Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. November 30, 2004; 1 -31 8. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2001; 356: 1423-30
  8. Bourezane Y, Salard D, Hoen B, et al. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin infect Dis 1998; 27: 1321-2
  9. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz 11. Ball RA, Kinchelow T, ISR Substudy Group. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 2003; 49: 826-31
  10. Hervey PS, Perry CM. Abacavir: â review of its clinical potential in patients with HIV infection. Drugs 2000; 60: 447-79
  11. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse- transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32
  12. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44
  13. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001; 77: 158-73
  14. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect DIs 2002; 34: 838-46
  15. Shah SS, Rodriguez T, McGowan JP. Miller Fisher variant of Guillain-Barre syndrome a